JOURNAL DESCRIPTION
The Medical Radiology and Radiation Safety journal ISSN 1024-6177 was founded in January 1956 (before December 30, 1993 it was entitled Medical Radiology, ISSN 0025-8334). In 2018, the journal received Online ISSN: 2618-9615 and was registered as an electronic online publication in Roskomnadzor on March 29, 2018. It publishes original research articles which cover questions of radiobiology, radiation medicine, radiation safety, radiation therapy, nuclear medicine and scientific reviews. In general the journal has more than 30 headings and it is of interest for specialists working in thefields of medicine¸ radiation biology, epidemiology, medical physics and technology. Since July 01, 2008 the journal has been published by State Research Center - Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency. The founder from 1956 to the present time is the Ministry of Health of the Russian Federation, and from 2008 to the present time is the Federal Medical Biological Agency.
Members of the editorial board are scientists specializing in the field of radiation biology and medicine, radiation protection, radiation epidemiology, radiation oncology, radiation diagnostics and therapy, nuclear medicine and medical physics. The editorial board consists of academicians (members of the Russian Academy of Science (RAS)), the full member of Academy of Medical Sciences of the Republic of Armenia, corresponding members of the RAS, Doctors of Medicine, professor, candidates and doctors of biological, physical mathematics and engineering sciences. The editorial board is constantly replenished by experts who work in the CIS and foreign countries.
Six issues of the journal are published per year, the volume is 13.5 conventional printed sheets, 88 printer’s sheets, 1.000 copies. The journal has an identical full-text electronic version, which, simultaneously with the printed version and color drawings, is posted on the sites of the Scientific Electronic Library (SEL) and the journal's website. The journal is distributed through the Rospechat Agency under the contract № 7407 of June 16, 2006, through individual buyers and commercial structures. The publication of articles is free.
The journal is included in the List of Russian Reviewed Scientific Journals of the Higher Attestation Commission. Since 2008 the journal has been available on the Internet and indexed in the RISC database which is placed on Web of Science. Since February 2nd, 2018, the journal "Medical Radiology and Radiation Safety" has been indexed in the SCOPUS abstract and citation database.
Brief electronic versions of the Journal have been publicly available since 2005 on the website of the Medical Radiology and Radiation Safety Journal: http://www.medradiol.ru. Since 2011, all issues of the journal as a whole are publicly available, and since 2016 - full-text versions of scientific articles. Since 2005, subscribers can purchase full versions of other articles of any issue only through the National Electronic Library. The editor of the Medical Radiology and Radiation Safety Journal in accordance with the National Electronic Library agreement has been providing the Library with all its production since 2005 until now.
The main working language of the journal is Russian, an additional language is English, which is used to write titles of articles, information about authors, annotations, key words, a list of literature.
Since 2017 the journal Medical Radiology and Radiation Safety has switched to digital identification of publications, assigning to each article the identifier of the digital object (DOI), which greatly accelerated the search for the location of the article on the Internet. In future it is planned to publish the English-language version of the journal Medical Radiology and Radiation Safety for its development. In order to obtain information about the publication activity of the journal in March 2015, a counter of readers' references to the materials posted on the site from 2005 to the present which is placed on the journal's website. During 2015 - 2016 years on average there were no more than 100-170 handlings per day. Publication of a number of articles, as well as electronic versions of profile monographs and collections in the public domain, dramatically increased the number of handlings to the journal's website to 500 - 800 per day, and the total number of visits to the site at the end of 2017 was more than 230.000.
The two-year impact factor of RISC, according to data for 2017, was 0.439, taking into account citation from all sources - 0.570, and the five-year impact factor of RISC - 0.352.
Medical Radiology and Radiation Safety. 2022. Vol. 67. № 6
DOI:10.33266/1024-6177-2022-67-6-67-73
I.D. Rozanov1, M.S. Bunak2, A.A. Glazkov2, E.A. Stepanova2, S.S. Lebedev1, A.S. Balkanov2
Postoperative Perfusion Magnetic Resonance Imaging as a Tool
for Predicting Survival in Glioblastoma of the Brain
1S.P. Botkin City Clinical Hospital, Outpatient Cancer Care Center, Moscow, Russia
2M.F. VladimirskyMoscow Regional Research Clinical Institute, Moscow, Russia
Contact person: Andrey Sergeevich Balkanov, e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
ABSTRACT
Glioblastoma is the most frequently detected primary brain tumor (pGB), the prognosis of which significantly depends on the magnitude of residual GB (rGB), for which magnetic resonance imaging (MRI) is used in the postoperative period.
Purpose: To analyze the data of ASL perfusion MRI (ASL-pMRI) performed prior to adjuvant radiation therapy (aRT), 6 to 8 weeks after resection of pGB, in terms of their prognostic significance for survival in this group of patients.
Material and methods: The study included 54 patients (median age ‒ 58 years; gender: 29 men, 25 women). The Karnovsky index in
81.5 % of patients was ≥80 %. To visualize and calculate the dimensions of the rGB, ASL-pMRI was used according to the type of pseudo-continuous three-dimensional marking of arterial spins. The focus/foci of hyperperfusion (CBFmean > 64 ml/100g/min) in the area of the wall of the postoperative cyst were considered as rGB.
Results: Survival in the total group of 54 patients with pGB was 18 months (95 % CI:14.23) . The use of ASL-pMRI made it possible to visualize rGB in 37 (68.5 %) patients. The probability of visualization of rGB was significantly higher (p=0.02) in the case of temporal localization of the tumor. Age (HR:1.04; 95 % CI: 1.01‒1.07; p=0.007), the maximum diameter of the rGB (HR:1.04; 95 % CI: (1.01‒1.07); p=0.03) and localization of pGB in the temporal lobe (HR:2.00; 95 % CI: 1.05‒3.80; p=0.034) had a significant negative impact on survival. The use of the multifactorial Cox model showed that only the age ≥60 years (HR:2.78; 95 % CI:1.26‒6.15; p=0.012) and the maximum diameter of rGB ≥25 mm (HR:3.35; 95 % CI:1.36‒8.22; p=0.008) retained their significant negative impact on the survival of patients with pGB.
Conclusions: the use of ASL – pMRI 6 to 8 weeks after resection of pGB indicates that the results obtained can become an effective tool for predicting survival in this group of patients.
Keywords: brain glioblastoma, ASL perfusion magnetic resonance imaging, residual glioblastoma, hyperperfusion focus, survival, radiation therapy
For citation: Rozanov ID, Bunak MS, Glazkov AA, Stepanova EA, Lebedev SS, Balkanov AS. Postoperative Perfusion Magnetic Resonance Imaging as a Tool for Predicting Survival in Glioblastoma of the Brain. Medical Radiology and Radiation Safety. 2022;67(6):67–73. (In Russian). DOI:10.33266/1024-6177-2022-67-6-67-73
References
1. Ostrom Q.T., Cote D.J., Ascha M., Kruchko C., Barnholtz-Sloan J.S. Adult Glioma Incidence and Survival by Race or Ethnicity in the United States from 2000 to 2014. JAMA Oncol. 2018;4;9:1254-1262. doi: 10.1001/jamaoncol.2018.1789.
2. Amirian E.S., Armstrong G.N., Zhou R., Lau C.C., Claus E.B., Barnholtz-Sloan J.S., Il’yasova D., Schildkraut J., Ali-Osman F., Sadetzki S., Johansen C., Houlston R.S, Jenkins R.B., Lachance D.,. Olson S.H., Bernstein J.L., Merrell R.T., Wrensch M.R., Davis F.G., Lai R., Shete S., Amos C.I., Scheurer M.E., Alafuzoff K.I., Brännström T., Broholm H., Collins P., Giannini C., Rosenblum M., Tihan T., Melin B.S., Bondy M.L. The Glioma International Case-control Study: A Report From the Genetic Epidemiology of Glioma International Consortium. Am. J. Epidemiol. 2016;183;2:85-91.
3. Chaichana K.L., Jusue-Torres I., Navarro-Ramirez R., Raza S.M., Pascual-Gallego M., Ibrahim A., Hernandez-Hermann M., Gomez L., Ye X., Weingart J.D., Olivi A., Blakeley J., Gallia G.L., Lim M., Brem H., Quinones-Hinojosa A. Establishing Percent Resection and Residual Volume Thresholds Affecting Survival and Recurrence for Patients with Newly Diagnosed Intracranial Glioblastoma. Neuro Oncol. 2014;16;1:113-122. doi: 10.1093/neuonc/not137.
4. Wen P.Y., Weller M., Lee E.Q., et al. Glioblastoma in Adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) Consensus Review on Current Management and Future Directions. Neuro Oncol. 2020;22;8:1073-1113. doi:10.1093/neuonc/noaa106.
5. Burth S., Kickingereder P., Eidel O., Tichy D., Bonekamp D., Weberling L., Wick A., Löw S., Hertenstein A., Nowosielski M., Schlemmer H.P., Wick W., Bendszus M., Radbruch A. Clinical Parameters Outweigh Diffusion- and Perfusion-Derived MRI Parameters in Predicting Survival in Newly Diagnosed Glioblastoma. Neuro Oncol. 2016;18;12:1673-1679. doi: 10.1093/neuonc/now122.
6. Molinaro A.M., Hervey-Jumper S., Morshed R.A., Young J., Han S.J., Chunduru P., Zhang Y., Phillips J.J., Shai A., Lafontaine M., Crane J., Chandra A., Flanigan P., Jahangiri A., Cioffi G., Ostrom Q., Anderson J.E., Badve C., Barnholtz-Sloan J., Sloan A.E., Erickson B.J., Decker P.A., Kosel M.L., LaChance D., Eckel-Passow J., Jenkins R., Villanueva-Meyer J., Rice T., Wrensch M., Wiencke J.K., Oberheim Bush N.A., Taylor J., Butowski N., Prados M., Clarke J., Chang S., Chang E., Aghi M., Theodosopoulos P., McDermott M., Berger M.S. Association of Maximal Extent of Resection of Contrast-Enhanced and Non-Contrast-Enhanced Tumor with Survival Within Molecular Subgroups of Patients with Newly Diagnosed Glioblastoma. JAMA Oncol. 2020;6;4:495-503. doi: 10.1001/jamaoncol.2019.6143. Erratum in: JAMA Oncol. 2020;6;3:444.
7. Kasper J., Hilbert N., Wende T., Fehrenbach M.K., Wilhelmy F., Jähne K., Frydrychowicz C., Hamerla G., Meixensberger J., Arlt F. On the Prognosis of Multifocal Glioblastoma: An Evaluation Incorporating Volumetric MRI. Curr Oncol. 2021;28;2:1437-1446. doi: 10.3390/curroncol28020136.
8. Ma R., Chari A., Brennan P.M., Alalade A., Anderson I., Solth A., Marcus H.J., Watts C., British Neurosurgical Trainee Research Collaborative. Residual Enhancing Disease after Surgery for Glioblastoma: Evaluation of Practice in the United Kingdom. Neurooncol Pract. 2018;5;2:74-81. doi: 10.1093/nop/npx023.
9. Wang P., Li J., Diao Q., Lin Y., Zhang J., Li L., Yang G., Fang X., Li X., Chen Y., Zheng L., Lu G. Assessment of Glioma Response to Radiotherapy Using 3D Pulsed-Continuous Arterial Spin Labeling and 3D Segmented Volume. Eur. J. Radiol. 2016;85;11:1987-1992. doi: 10.1016/j.ejrad.2016.08.009.
10. Batalov A.I., Zakharova N.Ye., Pogosbekyan E.L., Fadeyeva L.M., Goryaynov S.A., Bayev A.A., Shults Ye.I., Chelushkin D.M., Potapov A.A., Pronin I.N. Non-Contrast ASL Perfusion in Preoperative Diagnosis of Supratentorial Gliomas. Zhurnal Voprosy Neyrokhirurgii Imeni N.N. Burdenko = Burdenko’s Journal of Neurosurgery. 2018;82;6:15‑22. DOI 10.17116/neiro20188206115.
11. Marl H., Ertekin E., Tunçyürek Ö., Özsunar Y. Effects of Susceptibility Artifacts on Perfusion MRI in Patients with Primary Brain Tumor: A Comparison of Arterial Spin-Labeling versus DSC. AJNR Am. J. Neuroradiol. 2020;41;2:255-261. doi: 10.3174/ajnr.A6384.
12. Soni N., Dhanota D.P.S., Kumar S., Jaiswal A.K., Srivastava A.K. Perfusion MR Imaging of Enhancing Brain Tumors: Comparison of Arterial Spin Labeling Technique with Dynamic Susceptibility Contrast Technique. Neurol. India. 2017;65;5:1046-1052. doi: 10.4103/neuroindia.
13. Jovanovic M., Radenkovic S., Stosic-Opincal T., Lavrnic S., Gavrilovic S., Lazovic-Popovic B., Soldatovic I., Maksimovic R. Differentiation between Progression and Pseudoprogresion by Arterial Spin Labeling MRI in Patients with Glioblastoma Multiforme. J. BUON. 2017;22;4:1061-1067.
14. Xu Q., Liu Q., Ge H., Ge X., Wu J., Qu J., Xu K. Tumor Recurrence Versus Treatment Effects in Glioma: A Comparative Study of three Dimensional Pseudo-Continuous Arterial Spin Labeling and Dynamic Susceptibility Contrast Imaging. Medicine (Baltimore). 2017;96;50:e9332. doi: 10.1097/MD.0000000000009332.
15. Lindner T., Ahmeti H., Lübbing I., Helle M., Jansen O., Synowitz M., Ulmer S. Intraoperative Resection Control Using Arterial Spin Labeling - Proof of Concept, Reproducibility of Data and Initial Results. Neuroimage Clin. 2017;15:136-142. doi: 10.1016/j.nicl.2017.04.021.
16. Rebrikova V.A., Sergeev N.I., Padalko B.V., Kotlyarov P.M., Solodkiy V.A. The Use of Mr Perfusion in Assessing the Efficacy of Treatment for Malignant Brain Tumors. Zhurnal Voprosy Neyrokhirurgii Imeni N.N. Burdenko = Burdenko’s Journal of Neurosurgery. 2019;83;4:113-120 (In Russ.).
17. Kotlyarov P.M., Nudnov N.V., Vinikovetskaya A.V., Egorova E.V., Albitskiy I.A., Ovchinnikov V.I., Gombolevskiy V.A. Ct Perfusion in Diagnostic and Estimation Treatment Efficacy of Malignant Cranial Gliomas. Luchevaya Diagnostika i Terapiya = Diagnostic Radiology and Radiotherapy. 2015;2:63-69. (In Russ.).
18. Brown T.J., Brennan M.C., Li M., Church E.W., Brandmeir N.J., Rakszawski K.L., Patel A.S., Rizk E.B., Suki D., Sawaya R., Glantz M. Association of the Extent of Resection with Survival in Glioblastoma: A Systematic Review and Meta-Analysis. JAMA Oncol. 2016;2;11:1460-1469. doi: 10.1001/jamaoncol.2016.1373.
19. Garcia-Ruiz A., Naval-Baudin P., Ligero M., Pons-Escoda A., Bruna J., Plans G., Calvo N., Cos M., Majós C., Perez-Lopez R. Precise Enhancement Quantification in Post-Operative MRI as an Indicator of Residual Tumor Impact Is Associated with Survival in Patients with Glioblastoma. Sci Rep. 2021;11;1:695. doi: 10.1038/s41598-020-79829-3.
20. Laurent D., Freedman R., Cope L., Sacks P., Abbatematteo J., Kubilis P., Bova F., Rahman M. Impact of Extent of Resection on Incidence of Postoperative Complications in Patients with Glioblastoma. Neurosurgery. 2020;86;5:625-630. doi: 10.1093/neuros/nyz313.
21. Khashbat D., Harada M., Abe T., Ganbold M., Iwamoto S., Uyama N., Irahara S., Otomi Y., Kageji T., Nagahiro S. Diagnostic Performance of Arterial Spin Labeling for Grading Nonenhancing Astrocytic Tumors. Magn. Reson. Med. Sci. 2018;17;4:277-282. doi: 10.2463/mrms.mp.2017-0065.
22. Zeng Q., Jiang B., Shi F., Ling C., Dong F., Zhang J. 3D Pseudocontinuous Arterial Spin-Labeling MR Imaging in the Preoperative Evaluation of Gliomas. AJNR Am. J. Neuroradiol. 2017;38;10:1876-1883. doi: 10.3174/ajnr.A5299.
23. Falk Delgado A., De Luca F., van Westen D., Falk Delgado A. Arterial Spin Labeling MR Imaging for Differentiation between High- and Low-Grade Glioma-a Meta-Analysis. Neuro Oncol. 2018;20;11:1450-1461. doi:10.1093/neuonc/noy095.
24. Bag A.K., Cezayirli P.C., Davenport J.J., et al. Survival Analysis in Patients with Newly Diagnosed Primary Glioblastoma Multiforme Using Pre- and Post-Treatment Peritumoral Perfusion Imaging Parameters. J. Neurooncol. 2014;120;2:361‐370. doi:10.1007/s11060-014-1560-9.
25. Bunak M.S., Stepanova YE.A., Stashuk G.A. The Potentiality of Arterial Spins Labeling (ASL) Magnetic Resonance Perfusion Technique for the Diagnosis of Glioblastoma Residual Tissue. Almanakh Klinicheskoy Meditsiny = Almanac of Clinical Medicine. 2021;49;1:41–48. doi: 10.18786/2072-0505-2021-49-012 (In Russ.).
26. Kumar N., Kumar R., Sharma S.C., Mukherjee A., Khandelwal N., Tripathi M., Miriyala R., Oinam A.S., Madan R., Yadav B.S., Khosla D., Kapoor R. Impact of Volume of Irradiation on Survival and Quality of Life in Glioblastoma: a Prospective, Phase 2, Randomized Comparison of RTOG and MDACC Protocols. Neurooncol Pract. 2020;7;1:86-93. doi: 10.1093/nop/npz024.
27. Ali M.Y., Oliva C.R., Noman A.S.M., Allen B.G., Goswami P.C., Zakharia Y., Monga V., Spitz D.R., Buatti J.M., Griguer C.E. Radioresistance in Glioblastoma and the Development of Radiosensitizers. Cancers (Basel). 2020;12;9:2511. doi: 10.3390/cancers12092511.
28. Simpson J.R., Horton J., Scott C., Curran W.J., Rubin P., Fischbach J., Isaacson S., Rotman M., Asbell S.O., Nelson J.S., et al. Influence of Location and Extent of Surgical Resection on Survival of Patients with Glioblastoma Multiforme: Results of Three Consecutive Radiation Therapy Oncology Group (RTOG) Clinical Trials. Int. J. Radiat. Oncol. Biol. Phys. 1993;26;2:239-44. doi: 10.1016/0360-3016(93)90203-8.
29. Al-Holou W.N., Hodges T.R., Everson R.G., Freeman J., Zhou S., Suki D., Rao G., Ferguson S.D., Heimberger A.B., McCutcheon I.E., Prabhu S.S., Lang F.F., Weinberg J.S., Wildrick D.M., Sawaya R. Perilesional Resection of Glioblastoma Is Independently Associated With Improved Outcomes. Neurosurgery. 2020;86;1:112-121. doi: 10.1093/neuros/nyz008.
PDF (RUS) Full-text article (in Russian)
Conflict of interest. The authors declare no conflict of interest.
Financing. The study had no sponsorship.
Contribution. Article was prepared with equal participation of the authors.
Article received: 20.07.2022. Accepted for publication: 25.09.2022.